2 October 2015

New Collaboration Project to Develop Prostate Cancer Medication

The Institute of Pharmacology of Sherbrooke (IPS) and the Centre for Drug Research and Development (CDRD) have unveiled a project in which they have joined forces to accelerate the development of a new therapy for treating prostate cancer.

The specific goal of the partnership is to create an oral formulation—as opposed to the more invasive injection—for C23, an inhibitor of the PACE4 enzyme, which is associated with this type of cancer.

Preliminary studies by Dr. Robert Day, research professor at the Université de Sherbrooke and the Centre de recherche du CHUS (CRCHUS – Research Centre), have shown that the inhibitor slows the growth of prostate cancer tumours.

IPS-CDRD Pr Jean-Pierre Perreault, Pr Robert Day, Dr Sam White, and Pr Éric Marsault

Dr. Day and his team will therefore pursue their research in this regard. For its part, the CDRD will assess the safety aspect and the risk of side effects and may conduct more advanced chemical studies to resolve any potential problems.

This collaboration was announced during the second Sherbrooke International Life Sciences Summit (SILS) and is part of the recent association of these two organizations, in June 2015, to create the Sherbrooke-ACCESS-CDRD drug development node.

Sources: Université de Sherbrooke and CDRD
Photo credit: Robert Dumont



» Drug Development Hub in Sherbrooke

Back to the news

Leave a Reply

Your email address will not be published. Required fields are marked *

Sherbrooke Innopole’s mandate ends on March 31, 2024. We invite you to contact Entreprendre Sherbrooke or the Service du développement économique of the Ville de Sherbrooke for further services.
Thank you to all Sherbrooke industrial and technological businesses, as well as to all our partners for the trust granted since 2009!